Cargando…

Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters

SIMPLE SUMMARY: Counting the number of circulating tumor cells (CTCs) in blood samples has been recognized as being clinically useful. However, challenges like the rarity and heterogeneity of CTCs have limited their widespread use in clinical practice. To address these challenges, a feasible directi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Ngoc Anh, Huang, Po-Shuan, Chu, Po-Yu, Hsieh, Chia-Hsun, Wu, Min-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670359/
https://www.ncbi.nlm.nih.gov/pubmed/38001632
http://dx.doi.org/10.3390/cancers15225372
_version_ 1785139905292140544
author Nguyen, Thi Ngoc Anh
Huang, Po-Shuan
Chu, Po-Yu
Hsieh, Chia-Hsun
Wu, Min-Hsien
author_facet Nguyen, Thi Ngoc Anh
Huang, Po-Shuan
Chu, Po-Yu
Hsieh, Chia-Hsun
Wu, Min-Hsien
author_sort Nguyen, Thi Ngoc Anh
collection PubMed
description SIMPLE SUMMARY: Counting the number of circulating tumor cells (CTCs) in blood samples has been recognized as being clinically useful. However, challenges like the rarity and heterogeneity of CTCs have limited their widespread use in clinical practice. To address these challenges, a feasible direction is to combine the CTC counts with the routinely used clinical data relevant to cancer detection or screening for analysis. Recent studies demonstrate that this innovative approach has successfully improved cancer detection, prognosis, assessment, and the ability to differentiate between cancers at various stages and with different characteristics. The combination of CTC counts with clinical parameters represents a promising avenue for enhancing the clinical applicability of CTC analysis in cancer management. ABSTRACT: Analysis of circulating tumor cells (CTCs) holds promise to diagnose cancer or monitor its development. Among the methods, counting CTC numbers in blood samples could be the simplest way to implement it. Nevertheless, its clinical utility has not yet been fully accepted. The reasons could be due to the rarity and heterogeneity of CTCs in blood samples that could lead to misleading results from assays only based on single CTC counts. To address this issue, a feasible direction is to combine the CTC counts with other clinical data for analysis. Recent studies have demonstrated the use of this new strategy for early detection and prognosis evaluation of cancers, or even for the distinguishment of cancers with different stages. Overall, this approach could pave a new path to improve the technical problems in the clinical applications of CTC counting techniques. In this review, the information relevant to CTCs, including their characteristics, clinical use of CTC counting, and technologies for CTC enrichment, were first introduced. This was followed by discussing the challenges and new perspectives of CTC counting techniques for clinical applications. Finally, the advantages and the recent progress in combining CTC counts with other clinical parameters for clinical applications have been discussed.
format Online
Article
Text
id pubmed-10670359
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106703592023-11-11 Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters Nguyen, Thi Ngoc Anh Huang, Po-Shuan Chu, Po-Yu Hsieh, Chia-Hsun Wu, Min-Hsien Cancers (Basel) Review SIMPLE SUMMARY: Counting the number of circulating tumor cells (CTCs) in blood samples has been recognized as being clinically useful. However, challenges like the rarity and heterogeneity of CTCs have limited their widespread use in clinical practice. To address these challenges, a feasible direction is to combine the CTC counts with the routinely used clinical data relevant to cancer detection or screening for analysis. Recent studies demonstrate that this innovative approach has successfully improved cancer detection, prognosis, assessment, and the ability to differentiate between cancers at various stages and with different characteristics. The combination of CTC counts with clinical parameters represents a promising avenue for enhancing the clinical applicability of CTC analysis in cancer management. ABSTRACT: Analysis of circulating tumor cells (CTCs) holds promise to diagnose cancer or monitor its development. Among the methods, counting CTC numbers in blood samples could be the simplest way to implement it. Nevertheless, its clinical utility has not yet been fully accepted. The reasons could be due to the rarity and heterogeneity of CTCs in blood samples that could lead to misleading results from assays only based on single CTC counts. To address this issue, a feasible direction is to combine the CTC counts with other clinical data for analysis. Recent studies have demonstrated the use of this new strategy for early detection and prognosis evaluation of cancers, or even for the distinguishment of cancers with different stages. Overall, this approach could pave a new path to improve the technical problems in the clinical applications of CTC counting techniques. In this review, the information relevant to CTCs, including their characteristics, clinical use of CTC counting, and technologies for CTC enrichment, were first introduced. This was followed by discussing the challenges and new perspectives of CTC counting techniques for clinical applications. Finally, the advantages and the recent progress in combining CTC counts with other clinical parameters for clinical applications have been discussed. MDPI 2023-11-11 /pmc/articles/PMC10670359/ /pubmed/38001632 http://dx.doi.org/10.3390/cancers15225372 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nguyen, Thi Ngoc Anh
Huang, Po-Shuan
Chu, Po-Yu
Hsieh, Chia-Hsun
Wu, Min-Hsien
Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters
title Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters
title_full Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters
title_fullStr Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters
title_full_unstemmed Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters
title_short Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters
title_sort recent progress in enhanced cancer diagnosis, prognosis, and monitoring using a combined analysis of the number of circulating tumor cells (ctcs) and other clinical parameters
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670359/
https://www.ncbi.nlm.nih.gov/pubmed/38001632
http://dx.doi.org/10.3390/cancers15225372
work_keys_str_mv AT nguyenthingocanh recentprogressinenhancedcancerdiagnosisprognosisandmonitoringusingacombinedanalysisofthenumberofcirculatingtumorcellsctcsandotherclinicalparameters
AT huangposhuan recentprogressinenhancedcancerdiagnosisprognosisandmonitoringusingacombinedanalysisofthenumberofcirculatingtumorcellsctcsandotherclinicalparameters
AT chupoyu recentprogressinenhancedcancerdiagnosisprognosisandmonitoringusingacombinedanalysisofthenumberofcirculatingtumorcellsctcsandotherclinicalparameters
AT hsiehchiahsun recentprogressinenhancedcancerdiagnosisprognosisandmonitoringusingacombinedanalysisofthenumberofcirculatingtumorcellsctcsandotherclinicalparameters
AT wuminhsien recentprogressinenhancedcancerdiagnosisprognosisandmonitoringusingacombinedanalysisofthenumberofcirculatingtumorcellsctcsandotherclinicalparameters